Home / Business and Economy / Epigral's Q3 2025 Profits Plunge 37% Amid 6% Sales Decline
Epigral's Q3 2025 Profits Plunge 37% Amid 6% Sales Decline
10 Nov
Summary
- Epigral's net profit declined 37% to Rs 51.22 crore in Q3 2025
- Sales fell 6.18% to Rs 587.36 crore in Q3 2025 compared to Q3 2024
- Operating profit margin dropped from 28.50% to 22.48% year-over-year
In the third quarter of 2025, Epigral, a prominent company, faced a significant decline in its financial performance. The company's net profit plunged 37% to Rs 51.22 crore, down from Rs 81.30 crore in the same quarter of the previous year. This drop in profitability was primarily driven by a 6.18% decrease in sales, which fell from Rs 626.06 crore in Q3 2024 to Rs 587.36 crore in Q3 2025.
The company's operating profit margin also took a hit, declining from 28.50% in Q3 2024 to 22.48% in the latest quarter. This indicates that Epigral struggled to maintain its operational efficiency and cost control measures during the period.
The weakening financial performance of Epigral in the third quarter of 2025 highlights the challenges the company is facing in the current market environment. As the industry continues to evolve, Epigral will need to adapt its strategies and focus on improving its operational and financial metrics to regain its footing and drive sustainable growth.
